Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
3.470
-0.350 (-9.16%)
At close: Oct 23, 2026, 4:00 PM EDT
3.610
+0.140 (4.03%)
Pre-market: Oct 26, 2026, 5:39 AM EDT
Opus Genetics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Opus Genetics stock has a consensus rating of "Strong Buy" and an average price target of $13.47. The average 1-year stock price forecast is 288.18% higher than the current stock price, while the lowest is $8.00 (+130.55%) and the highest is $20 (+476.37%).
Price Target: $13.47 (+288.18%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 15 | 16 | 16 | 15 | 15 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 18 | 19 | 19 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $20 | Buy | Reiterates | $20 | +476.37% | Oct 21, 2026 |
| Wedbush | Wedbush | Buy Maintains $13 | Buy | Maintains | $13 | +274.64% | Oct 19, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $17 | Buy | Maintains | $17 | +389.91% | Oct 19, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $14 → $15 | Buy | Reiterates | $14 → $15 | +332.28% | Oct 19, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 | Buy | Maintains | $11 | +217.00% | Oct 16, 2026 |
Financial Forecast
Revenue This Year
13.75M
from 14.20M
Decreased by -3.14%
Revenue Next Year
13.62M
from 13.75M
Decreased by -0.91%
EPS This Year
-0.94
from -0.80
EPS Next Year
-0.72
from -0.94
EPS and Forward PE are based on non-GAAP adjusted numbers.